Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Pipeline Insight, 2024

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Pipeline Insight, 2024

DelveInsight’s, “Mucosa-associated Lymphoid Tissue (MALT) Lymphoma – Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Understanding

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Overview

MALT lymphoma belongs to a group of non-Hodgkin lymphomas called marginal zone lymphomas. It is a low grade (slow growing) non-Hodgkin lymphoma (NHL) that starts in the mucosa which lines some body organs and cavities. MALT lymphoma can affect people of any age but it typically develops in people in their mid-60s. MALT lymphoma is more common in people who have been infected with certain viruses or who have particular autoimmune conditions. The symptoms of MALT lymphoma depend on where the lymphoma develops. Unlike many other types of lymphoma, MALT lymphoma develops outside the lymph nodes. It does not usually cause swollen lymph nodes. People with MALT lymphoma very rarely experience ‘B symptoms. MALT lymphoma is usually diagnosed by removing a sample of tissue and looking at it under a microscope. This involves a small operation called a biopsy, which is usually done under a local anaesthetic. Surgery is used very occasionally if the lymphoma is only affecting one part of body and is in an area where it can be safely removed.

""Mucosa-associated Lymphoid Tissue (MALT) Lymphoma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline landscape is provided which includes the disease overview and Mucosa-associated Lymphoid Tissue (MALT) Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Mucosa-associated Lymphoid Tissue (MALT) Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mucosa-associated Lymphoid Tissue (MALT) Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Mucosa-associated Lymphoid Tissue (MALT) Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Mucosa-associated Lymphoid Tissue (MALT) Lymphoma.

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Emerging Drugs Chapters

This segment of the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Emerging Drugs

• Tafasitamab: Morphosys

Tafasitamab (MOR208, formerly Xmab®5574) is an investigational monoclonal antibody directed against the antigen CD19 which is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. The InMIND Study is a Phase III double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R follicular lymphoma (FL) Grade 1 to 3a or R/R marginal zone lymphoma (MZL).

• Zandelisib/ MEI Pharma

Zandelisib is being evaluated in multiple clinical studies, including COASTAL, a Phase III study, and TIDAL, a Phase II study, both of which are evaluating zandelisib in patients with relapsed and refractory follicular and marginal zone lymphomas. The development and planned commercialization of zandelisib is being conducted in partnership with Kyowa Kirin Co., Ltd. (“KKC”). MEI and KKC will co-develop and co-promote zandelisib in the U.S., with MEI recording all revenue from U.S. sales. KKC has exclusive commercialization rights outside of the U.S. COASTAL is intended to support full marketing applications in the U.S. and globally in relapsed or refractory follicular lymphoma and marginal zone lymphoma patients who have received at least one prior line of treatment. COASTAL is also intended to act as the required confirmatory study for the potential U.S. accelerated approval of zandelisib based on the TIDAL study. FDA has granted zandelisib Fast Track designation.

Further product details are provided in the report……..

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Mucosa-associated Lymphoid Tissue (MALT) Lymphoma

There are approx. 8+ key companies which are developing the therapies for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma. The companies which have their Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Morphosys.

• Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mucosa-associated Lymphoid Tissue (MALT) Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs.

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Report Insights

• Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs?
• How many Mucosa-associated Lymphoid Tissue (MALT) Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mucosa-associated Lymphoid Tissue (MALT) Lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Mucosa-associated Lymphoid Tissue (MALT) Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Mucosa-associated Lymphoid Tissue (MALT) Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?